Jin-Young Son

Pyeongtaek Dongbang I-Port Co., Ltd. provides port construction and management services. It operates as a holding company with interests in constructs and operates ports and manages cargos and terminals. The firm owns terminal equipments including gantry and transfer crane, reach stacker, and top handler. Pyeongtaek Dongbang I-Port was founded in November 2005 and is headquartered in Pyeongtaek, South Korea.

Pocheon Power Co., Ltd. constructs and operates combined liquefied natural gas based power plants. The firm distributes electric power to metropolitan areas in South Korea. Its business fields are Power Plant, Future Plan, and Green Energy. The company was founded on July 24, 2008 and is headquartered in Pocheon, South Korea.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. Celleron has deep relationships with Oxford University and is located on the Oxford Science Park. The British company focuses on the clinical development of new and innovative therapies to treat cancer. Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The company's lead products are currently in clinical trials, and they have a biomarker platform that allows them to identify responsive patients. Celleron Therapeutics Ltd. was founded in 2004, and the CEO is Nick la Thangue.